In the absence of randomized trials on the effects of acetaminophen, researchers need to use 'natural experiments' to develop better guidance for patients. ...

There hasn't been much good news lately for this Johnson & Johnson spinoff.Johnson & Johnson (JNJ 2.05%) spun off its consumer health unit as a separate entity in 2023. The new business, Kenvue (KVUE -0.77%), inherited a broad lineup of popular products, including Band-Aid adhesive bandages, Listerine mouthwash, Tylenol pain reliever, and Zyrtec allergy medicine. With an arsenal of household names in its lineup and a solid dividend, Kenvue seemed to be the kind of stock many income investors would love. How ...

Cullen Dumps 6.6M KVUE Shares Worth $149.5 MillionCullen Capital Management, LLC disclosed the sale of 6,565,339 shares of Kenvue (KVUE -0.77%) for the period ended Q2 2025. The transaction was valued at an estimated $149.46 million.What happenedCullen Capital Management, LLC reported in a September 30, 2025SEC filingthat it reduced its position in Kenvue by 6,565,339 shares during Q2 2025. The estimated value of the shares sold was $149.46 million, based on the average closing price for the quarter. After ...

Kenvue (NYSE: KVUE ) has seen its fair share of headwinds in the last year, with the most recent one from the Trump administration.Contributing analyst to the iREIT+Hoya Capital investment group. The Dividend Collectuh is not a registered investment professional nor financial advisor and these articles should not be taken as financial advice. This is for educational purposes only and I encourage everyone to do their own due diligence. I'm a Navy veteran who enjoys dividend investing in quality blue-chip sto ...

The CEO behind Tylenol thought he'd found a way to work with the Trump administration. Then everything went off the rails. ...

U.S. President Donald Trump on Friday repeated his call for pregnant women and young children to stop using popular pain medication Tylenol, defying widespread criticism from medical groups, and offer... ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades: Rothschild & Co Redburn upgraded Kenvue (KVUE) to Buy from Neutral with a price target of $22, down from $22.50. The shares are down over 20% this month with the Trump administering linking usage of Tylenol by expectant mothers with an increased risk of autism in infants, but the firm views proposals laid out th ...

We recently published 14 Stocks Jim Cramer Discussed Including His 2 Top Quantum Computing Stocks. Kenvue Inc. (NYSE:KVUE) is one of the stocks Jim Cramer recently discussed. Kenvue Inc. (NYSE:KVUE) has been in the news lately after President Trump asserted that taking Tylenol can increase autism in unborn children. The firm’s shares have lost 22% over the month. Before the President’s remarks, Cramer commented in a Mad Money episode that he didn’t believe Kenvue Inc. (NYSE:KVUE)’s litigation risks were a ...

Secretary of Health and Human Services Robert F. Kennedy Jr.The Associated PressTylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop there.Tylenol may be only the beginning.For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and ...

A 2017 post by Tylenol on X (formerly Twitter) highlighted by White House has fueled a buzz around President Donald Trump‘s claim that the drug is linked with autism in kids.HHS, White House Reshare 2017 Tylenol TweetThe Department of Health and Human Services and the White House on Wednesday shared a March 2017 tweet from the official Tylenol account, reigniting the debate about the potential link between the popular pain reliever and autism. The tweet in question was a response to a customer’s now-deleted ...